News & analysis
Times are shown in BST, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilises Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The main country of operation is in the UK.
Latest BVX News
BVX Regulatory News